Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Classical conditioning of antidepressant placebo effects in mice.

Krimmel SR, Zanos P, Georgiou P, Colloca L, Gould TD.

Psychopharmacology (Berl). 2019 Aug 17. doi: 10.1007/s00213-019-05347-4. [Epub ahead of print]

PMID:
31422429
2.

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.

Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD.

Neuropsychopharmacology. 2019 Jun 19. doi: 10.1038/s41386-019-0443-3. [Epub ahead of print]

PMID:
31216563
3.

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.

Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD.

Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13.

PMID:
30941749
4.

Group II metabotropic glutamate receptor blockade promotes stress resilience in mice.

Highland JN, Zanos P, Georgiou P, Gould TD.

Neuropsychopharmacology. 2019 Sep;44(10):1788-1796. doi: 10.1038/s41386-019-0380-1. Epub 2019 Apr 2.

PMID:
30939596
5.

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.

6.

Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation.

Georgiou P, Zanos P, Jenne CE, Gould TD.

Front Psychiatry. 2019 Feb 26;10:81. doi: 10.3389/fpsyt.2019.00081. eCollection 2019.

7.

Alpha2B-Adrenergic Receptor Overexpression in the Brain Potentiate Air Pollution-induced Behavior and Blood Pressure Changes.

Rao X, Asico LD, Zanos P, Mahabeleshwar GH, Singh Gangwar R, Xia C, Duan L, Cisse YM, Rengasamy P, Jose PA, Gould TD, Nelson R, Biswal S, Chen LC, Zhong J, Rajagopalan S.

Toxicol Sci. 2019 May 1;169(1):95-107. doi: 10.1093/toxsci/kfz025.

PMID:
30812033
8.

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.

Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.

9.

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.

Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA Jr, Thomas CJ, Moaddel R, Gould TD.

J Psychopharmacol. 2018 Nov 29:269881118812095. doi: 10.1177/0269881118812095. [Epub ahead of print]

PMID:
30488740
10.

Chronic nicotine administration restores brain region specific upregulation of oxytocin receptor binding levels in a G72 mouse model of schizophrenia.

Zanos P, Keyworth H, Georgiou P, Hambsch B, Otte DM, Kitchen I, Zimmer A, Bailey A.

Eur J Neurosci. 2019 Aug;50(3):2255-2263. doi: 10.1111/ejn.14155. Epub 2018 Oct 10.

PMID:
30218618
11.

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD.

Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Review. Erratum in: Pharmacol Rev. 2018 Oct;70(4):879.

12.

Environmental enrichment enhances conditioned place preference to ethanol via an oxytocinergic-dependent mechanism in male mice.

Rae M, Zanos P, Georgiou P, Chivers P, Bailey A, Camarini R.

Neuropharmacology. 2018 Aug;138:267-274. doi: 10.1016/j.neuropharm.2018.06.013. Epub 2018 Jun 21.

PMID:
29908241
13.

Isoflurane but not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?

Brown PL, Zanos P, Wang L, Elmer GI, Gould TD, Shepard PD.

Int J Neuropsychopharmacol. 2018 Mar 15. doi: 10.1093/ijnp/pyy029. [Epub ahead of print]

14.

Mechanisms of ketamine action as an antidepressant.

Zanos P, Gould TD.

Mol Psychiatry. 2018 Apr;23(4):801-811. doi: 10.1038/mp.2017.255. Epub 2018 Mar 13. Review.

15.

Convergent Mechanisms Underlying Rapid Antidepressant Action.

Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD.

CNS Drugs. 2018 Mar;32(3):197-227. doi: 10.1007/s40263-018-0492-x. Review.

16.

Methamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways.

García-Carmona JA, Georgiou P, Zanos P, Bailey A, Laorden ML.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):423-434. doi: 10.1007/s00210-018-1470-z. Epub 2018 Jan 30.

PMID:
29383398
17.

Wheel running during chronic nicotine exposure is protective against mecamylamine-precipitated withdrawal and up-regulates hippocampal α7 nACh receptors in mice.

Keyworth H, Georgiou P, Zanos P, Rueda AV, Chen Y, Kitchen I, Camarini R, Cropley M, Bailey A.

Br J Pharmacol. 2018 Jun;175(11):1928-1943. doi: 10.1111/bph.14068. Epub 2017 Dec 22.

18.

Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions.

Zanos P, Gould TD.

Biol Psychiatry. 2018 Jan 1;83(1):2-4. doi: 10.1016/j.biopsych.2017.10.026. No abstract available.

19.

Correction to "Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites".

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Oct 6;19(19):5494. doi: 10.1021/acs.orglett.7b02839. Epub 2017 Sep 21. No abstract available.

PMID:
28933164
20.

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Sep 1;19(17):4572-4575. doi: 10.1021/acs.orglett.7b02177. Epub 2017 Aug 22. Erratum in: Org Lett. 2017 Oct 6;19(19):5494.

21.

Dopamine and Stress System Modulation of Sex Differences in Decision Making.

Georgiou P, Zanos P, Bhat S, Tracy JK, Merchenthaler IJ, McCarthy MM, Gould TD.

Neuropsychopharmacology. 2018 Jan;43(2):313-324. doi: 10.1038/npp.2017.161. Epub 2017 Jul 25.

22.

Zanos et al. reply.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD.

Nature. 2017 Jun 21;546(7659):E4-E5. doi: 10.1038/nature22085. No abstract available.

23.

Animal models to improve our understanding and treatment of suicidal behavior.

Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT.

Transl Psychiatry. 2017 Apr 11;7(4):e1092. doi: 10.1038/tp.2017.50. Review.

24.

Oxytocin and opioid addiction revisited: old drug, new applications.

Zanos P, Georgiou P, Weber C, Robinson F, Kouimtsidis C, Niforooshan R, Bailey A.

Br J Pharmacol. 2018 Jul;175(14):2809-2824. doi: 10.1111/bph.13757. Epub 2017 Apr 6. Review.

25.

A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.

Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM.

eNeuro. 2017 Mar 7;4(1). pii: ENEURO.0285-16.2017. doi: 10.1523/ENEURO.0285-16.2017. eCollection 2017 Jan-Feb.

26.

Transient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3-/- mice, but not wildtype mice.

Martynhak BJ, Hogben AL, Zanos P, Georgiou P, Andreatini R, Kitchen I, Archer SN, von Schantz M, Bailey A, van der Veen DR.

Sci Rep. 2017 Jan 10;7:40399. doi: 10.1038/srep40399.

27.

Ketamine Mechanism of Action: Separating the Wheat from the Chaff.

Gould TD, Zanos P, Zarate CA Jr.

Neuropsychopharmacology. 2017 Jan;42(1):368-369. doi: 10.1038/npp.2016.210. No abstract available.

28.

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Zanos P, Moaddel R, Morris PJ, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD.

Biol Psychiatry. 2017 Apr 15;81(8):e69-e71. doi: 10.1016/j.biopsych.2016.08.039. Epub 2016 Sep 30. No abstract available.

29.

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD.

J Pharmacol Exp Ther. 2016 Oct;359(1):159-70. doi: 10.1124/jpet.116.235838. Epub 2016 Jul 28.

30.

Cocaine abstinence induces emotional impairment and brain region-specific upregulation of the oxytocin receptor binding.

Georgiou P, Zanos P, Hourani S, Kitchen I, Bailey A.

Eur J Neurosci. 2016 Oct;44(7):2446-2454. doi: 10.1111/ejn.13348. Epub 2016 Aug 10.

PMID:
27453431
31.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD.

Nature. 2016 May 26;533(7604):481-6. doi: 10.1038/nature17998. Epub 2016 May 4.

32.

Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype.

Georgiou P, Zanos P, Garcia-Carmona JA, Hourani S, Kitchen I, Laorden ML, Bailey A.

Neuropharmacology. 2016 Jun;105:520-532. doi: 10.1016/j.neuropharm.2016.02.012. Epub 2016 Feb 16.

PMID:
26896754
33.

Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction.

Zanos P, Georgiou P, Gonzalez LR, Hourani S, Chen Y, Kitchen I, Kieffer BL, Winsky-Sommerer R, Bailey A.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw011. doi: 10.1093/ijnp/pyw011. Print 2016 Jul.

34.

The oxytocin analogue carbetocin prevents priming-induced reinstatement of morphine-seeking: Involvement of dopaminergic, noradrenergic and MOPr systems.

Georgiou P, Zanos P, Garcia-Carmona JA, Hourani S, Kitchen I, Kieffer BL, Laorden ML, Bailey A.

Eur Neuropsychopharmacol. 2015 Dec;25(12):2459-64. doi: 10.1016/j.euroneuro.2015.09.015. Epub 2015 Oct 9.

PMID:
26475574
35.

The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA Jr, Schwarcz R, Gould TD.

J Pharmacol Exp Ther. 2015 Oct;355(1):76-85. doi: 10.1124/jpet.115.225664. Epub 2015 Aug 11.

36.

Region-specific up-regulation of oxytocin receptor binding in the brain of mice following chronic nicotine administration.

Zanos P, Georgiou P, Metaxas A, Kitchen I, Winsky-Sommerer R, Bailey A.

Neurosci Lett. 2015 Jul 23;600:33-7. doi: 10.1016/j.neulet.2015.05.054. Epub 2015 May 30.

PMID:
26037668
37.

Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav 1.2).

Zanos P, Bhat S, Terrillion CE, Smith RJ, Tonelli LH, Gould TD.

Eur J Neurosci. 2015 Oct;42(8):2499-507. doi: 10.1111/ejn.12952. Epub 2015 Jun 23.

38.

A critical role of striatal A2A R-mGlu5 R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine.

Wright SR, Zanos P, Georgiou P, Yoo JH, Ledent C, Hourani SM, Kitchen I, Winsky-Sommerer R, Bailey A.

Addict Biol. 2016 Jul;21(4):811-25. doi: 10.1111/adb.12259. Epub 2015 May 15.

PMID:
25975203
39.

Differential regulation of mGlu5 R and ΜOPr by priming- and cue-induced reinstatement of cocaine-seeking behaviour in mice.

Georgiou P, Zanos P, Ehteramyan M, Hourani S, Kitchen I, Maldonado R, Bailey A.

Addict Biol. 2015 Sep;20(5):902-12. doi: 10.1111/adb.12208. Epub 2014 Dec 17.

PMID:
25522112
40.

Epigenetically modified nucleotides in chronic heroin and cocaine treated mice.

Chao MR, Fragou D, Zanos P, Hu CW, Bailey A, Kouidou S, Kovatsi L.

Toxicol Lett. 2014 Sep 17;229(3):451-7. doi: 10.1016/j.toxlet.2014.07.023. Epub 2014 Jul 23.

PMID:
25064621
41.

The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice.

Zanos P, Georgiou P, Wright SR, Hourani SM, Kitchen I, Winsky-Sommerer R, Bailey A.

Neuropsychopharmacology. 2014 Mar;39(4):855-65. doi: 10.1038/npp.2013.285. Epub 2013 Oct 15.

42.

Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism.

Zanos P, Wright SR, Georgiou P, Yoo JH, Ledent C, Hourani SM, Kitchen I, Winsky-Sommerer R, Bailey A.

Pharmacol Biochem Behav. 2014 Apr;119:72-9. doi: 10.1016/j.pbb.2013.05.009. Epub 2013 May 13.

PMID:
23680573
43.

Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver.

Fragou D, Zanos P, Kouidou S, Njau S, Kitchen I, Bailey A, Kovatsi L.

Toxicol Lett. 2013 Apr 26;218(3):260-5. doi: 10.1016/j.toxlet.2013.01.022. Epub 2013 Feb 20.

PMID:
23454526

Supplemental Content

Support Center